A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant
Titel:
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant
Auteur:
Sawicki, Gregory S. Chilvers, Mark McNamara, John Naehrlich, Lutz Saunders, Clare Sermet-Gaudelus, Isabelle Wainwright, Claire E. Ahluwalia, Neil Campbell, Daniel Harris, R. Scott Paz-Diaz, Hildegarde Shih, Judy L. Davies, Jane C.